[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7669 Introduced in House (IH)]
<DOC>
117th CONGRESS
2d Session
H. R. 7669
To require guidance on extending expiration dates for certain drugs,
and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 6, 2022
Ms. Matsui introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To require guidance on extending expiration dates for certain drugs,
and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Drug Shortages Shelf Life Extension
Act''.
SEC. 2. EXTENDING EXPIRATION DATES FOR CERTAIN DRUGS.
(a) In General.--Not later than 1 year after the date of enactment
of this Act, the Secretary of Health and Human Services (referred to in
this section as the ``Secretary'') shall issue draft guidance, or
revise existing guidance, to address recommendations for sponsors of
applications submitted under section 505 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355) or section 351 of the Public Health
Service Act (42 U.S.C. 262) regarding--
(1) the submission of stability testing data in such
applications, including considerations for data requirements
that could be streamlined or reduced to facilitate faster
review of longer proposed expiration dates;
(2) establishing in the labeling of drugs the longest
feasible expiration date scientifically supported by such data,
taking into consideration how extended expiration dates may--
(A) help prevent or mitigate drug shortages; and
(B) affect product quality; and
(3) the use of innovative approaches for drug and
combination product stability modeling to support initial
product expiration dates and expiration date extensions.
(b) Report.--Not later than 2 years after the date of enactment of
this Act, and again 2 years thereafter, the Secretary shall submit to
the Committee on Health, Education, Labor, and Pensions of the Senate
and the Committee on Energy and Commerce of the House of
Representatives a report that includes--
(1) the number of drugs for which the Secretary has
requested the manufacturer make a labeling change regarding the
expiration date; and
(2) for each drug for which the Secretary has requested a
labeling change with respect to the expiration date,
information regarding the circumstances of such request,
including--
(A) the name and dose of such drug;
(B) the rationale for the request;
(C) whether the drug, at the time of the request,
was listed on the drug shortage list under section 506E
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
356e), or was at risk of shortage;
(D) whether the request was made during a public
health emergency declared under section 319 of the
Public Health Service Act (42 U.S.C. 247d); and
(E) whether the manufacturer made the requested
change by the requested date, and for instances where
the manufacturer does not make the requested change,
the manufacturer's justification for not making the
change, if the manufacturer agrees to provide such
justification for inclusion in the report.
<all>